Functional assessment of CYP3A4 and CYP2C19 genetic polymorphisms on the metabolism of clothianidin in vitro

被引:0
|
作者
Hu, Yingying [1 ]
Ye, Zhize [2 ]
Wu, Hualu [1 ]
Chen, Xiaohai [1 ]
Xia, Hailun [1 ]
Cai, Jian-ping [3 ]
Hu, Guo-xin [4 ]
Xu, Ren-ai [1 ]
机构
[1] Wenzhou Med Univ, Affiliated Hosp 1, Nanbaixiang St, Wenzhou 325000, Zhejiang, Peoples R China
[2] Shaoxing Peoples Hosp, Shaoxing, Zhejiang, Peoples R China
[3] Chinese Acad Med Sci, Inst Geriatr Med, Key Lab Geriatr,Beijing Inst Geriatr, Beijing Hosp,Natl Ctr Gerontol,Natl Hlth Commiss, Beijing, Peoples R China
[4] Wenzhou Med Univ, Inst Mol Toxicol & Pharmacol, Sch Pharmaceut Sci, Wenzhou, Zhejiang, Peoples R China
关键词
Clothianidin; Variants; Metabolism; ALLELIC VARIANTS; RAPID METABOLIZER; IDENTIFICATION; GENOTYPE; EXPOSURE; ENZYMES; RISK;
D O I
10.1016/j.cbi.2024.111154
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Clothianidin, classified as a second-generation neonicotinoid, has achieved extensive application due to its high efficacy against insect pests. This broad-spectrum usage has resulted in its frequent detection in environmental surveys. CYP2C19 and CYP3A4 are crucial for converting clothianidin to desmethyl-clothianidin (dm-clothianidin). The expression of these CYP450s can be significantly influenced by genetic polymorphisms. The objective of our research was to examine the catalytic effects of 27 CYP3A4 variants and 31 CYP2C19 variants on the metabolism of clothianidin within recombinant insect microsomes. These variants were assessed through a wellestablished incubation procedure. In addition, the concentration of its metabolite dm-clothianidin was quantified by employing an ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS). Lastly, the kinetic parameters of these CYP3A4 and CYP2C19 variants were calculated by applying Michaelis-Menten kinetic analysis to fit the data. The observed changes in enzyme activity were related to the metabolic transformation of clothianidin to dm-clothianidin. In the CYP2C19 metabolic pathway, one variant (CYP2C19.23) showed no notable change in intrinsic clearance (CLint), four variants (CYP2C19.29, .30, .31 and L16F) demonstrated a marked increase in CLint(110.86-183.46 %), and the remaining 25 variants exhibited a considerable decrease in CLint(26.38-89.79 %), with a maximum decrease of 73.62 % (CYP2C19.6). In the CYP3A4 metabolic pathway, 26 variants demonstrated significantly reduced CLint(10.54-52.52 %), with a maximum decrease of 89.46 % (CYP3A4.20). Our results suggested that most variants of CYP3A4 and CYP2C19 significantly altered the enzymatic activities associated with clothianidin metabolism to various degrees. This study provides new insights into assessing the metabolic behavior of pesticides and delivers crucial data that can guide clinical detoxification strategies.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes
    Katsuki, H
    Hamada, A
    Nakamura, C
    Arimori, K
    Nakano, M
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 57 (10) : 709 - 715
  • [22] The roles of CYP2C19 and CYP3A4 in the in vitro metabolism of β-eudesmol in human liver: Reaction phenotyping and enzyme kinetics
    Muhamad, Nadda
    Na-Bangchang, Kesara
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2023, 11 (06):
  • [23] Assessment of CYP2C19 genetic polymorphisms in a korean population using a simultaneous multiplex pyrosequencing method to simultaneously detect the CYP2C19*2, CYP2C19*3, and CYP2C19*17 alleles
    Kim, K. -A.
    Song, W. -K.
    Kim, K. -R.
    Park, J. -Y.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2010, 35 (06) : 697 - 703
  • [24] Genetic Polymorphisms and in Vitro Functional Characterization of CYP2C8, CYP2C9, and CYP2C19 Allelic Variants
    Hiratsuka, Masahiro
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2016, 39 (11) : 1748 - 1759
  • [25] Response to "Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped" - The Role of CYP3A4 and CYP3A5 Polymorphisms in Clinical Pharmacokinetics of Voriconazole
    Walsh, T. J.
    Moriyama, B.
    Penzak, S. R.
    Klein, T. E.
    Caudle, K. E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 102 (02) : 190 - 190
  • [26] GENETIC POLYMORPHISMS OF CYTOCHROME P450 (CYP) 2C9, CYP2C19, CYP2D6, CYP3A4, AND CYP3A5 IN A KORSIAN POPULATION
    Lim, Y.
    Kim, E.
    Lee, Y.
    Cha, E.
    Jung, H.
    Kim, J.
    Lee, S.
    Shin, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S61 - S61
  • [27] CYP2C19 and CYP3A4 gene variants and schizophrenia in Armenian patients
    Butenko, E. V.
    Mamedov, R. F. O.
    Ghazaryan, H. K.
    Zakharyan, R. V.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 269 - 270
  • [28] Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped
    Gautier-Veyret, E.
    Fonrose, X.
    Stanke-Labesque, F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 102 (02) : 189 - 189
  • [29] Imipramine demethylation in vivo: Impact of CYP1A2, CYP2C19, and CYP3A4
    Madsen, H
    Rasmussen, BB
    Brosen, K
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (03) : 319 - 324
  • [30] Effects of CYP2C19, CYP2C9 and CYP3A4 gene polymorphisms on plasma voriconazole levels in Chinese pediatric patients
    Fan, Xinghua
    Zhang, Hong
    Wen, Zhipeng
    Zheng, Xiaoli
    Yang, Yi
    Yang, Jihong
    PHARMACOGENETICS AND GENOMICS, 2022, 32 (04): : 152 - 158